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ABSTRACT
A combination of bupropion hydrochloride and thiothixene was

compared with a combination of placebo and thiothixene in a double blind
investigation in thirty-eight patients meeting the DSM-III criteria for
schizophrenia and also for atypical depression. These patients had to
demonstrate a Hamilton Depression Scale score of at least eighteen prior
to study entry. Assessments for efficacy and safety were performed at
baseline and at regular intervals throughout the study.

Patients were

given physical exams with complete clinical laboratory workups prior to
and after the study active treatment phase to document the safety of the
respective treatments.
Of the nineteen subjects originally included in each treatment
group, eighteen completed four full weeks of study treatment.

Patients

in both treatment groups were not significantly different at baseline on
all measures. A significantly greater number of subjects (9) dropped out
from the bupropion and thiothixene group than from the placebo and
thiothixene group (2) prior to reaching the full ten week period. The
patients who dropped out were significantly more psychiatrically ill
than those who remained as measured by the Brief Psychiatric Rating
Scale.
Both groups became less depressed as measured on the Hamilton
Depression Scale over four and ten weeks, though only when the dropouts
were included in the analysis did the placebo and thiothixene group
demonstrate a greater degree of improvement than the bupropion and
thiothixene group.

The overall psychiatric pathology as measured by the

Brief Psychiatric Rating Scale was decreased to a significantly greater

degree by the placebo and thiothixene control group than by the
bupropion and thiothixene group at four weeks but not at ten weeks.
Global ratings of patients overall psychiatric status also showed
improvement over time.
Treatment group effects on separate psychiatric syndromes as
measured by the Brief Psychiatric Rating Scale factor scores were
divergent.

Significant decreases on the thought disorder and the

anergia factor scores from baseline were observed for both treatment
groups to a similar degree.

However, patients in the thiothixene and

placebo group demonstrated greater improvement over time than the
bupropion and thiothixene group on the anxiety and depression factor
score.

Neither group showed improvement from baseline on the activation

factor scores nor the hostilty and depression factor scores.
Neurological side effects were not significantly different between
groups. No differences between group were observed on the physical and
clinical chemistry examinations of patient health nor on
electrocardiogram or electroencephalogram.

The Treatment Emergent

Symptom Scale showed statistically significant between group
differences. The bupropion and thiothixene group reported twice the
incidence of dry mouth and constipation than the placebo and thiothixene
group, while the latter group reported increase in appetite, more
menstrual disturbances, and a decrease in sex drive over four and ten
weeks.
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INTRODUCTION
The treatment of depressive syndromes in schizophrenic patients has
been problematic.

The tricyclic antidepressants (TCA's) and monoamine

oxidase inhibitors (MAOI's) have not been shown to be effective in
treating depression as a secondary symptom of schizophrenia (Becker,
1985; Siris et al., 1978), and in fact have been implicated in inducing
psychosis in previously stabilized schizophrenic patients (Siris et al.,
1978).

While some antipsychotic medications have been shown to be

effective in treating both psychosis and depression (Becker, 1983),
there is no established treatment for depression coexisting with
schizophrenia if depression does not resolve as a result of treatment
with the antipsychotic phenothiazines or butyrophenones.

Furthermore,

clinically significant symptoms of depression of ten occur in patients
who have had their psychosis succesfully treated with antipsychotics
(Mandel et al., 1982).

Depression often is a secondary symptom in

schizophrenia (Weisman et al., 1977; Siris et al., 1981; Carr, 1983;
Becker,1985), and depressed schizophrenics are more likely to relapse
following successful treatment than nondepressed schizophrenics (Mandel
et al., 1982; Glazer et al., 1981).
The primary focus of the present study is to attempt to
successfully treat this resistant patient population with the novel
antidepressant bupropion.

The pharmacological profile of this

chemically distinct antidepressant makes it unlikely that it will
potentiate the sedative and anticholinergic properties of the
antipsychotic drugs, thus making the use of this medication in
combination with antipsychotics feasible.

As the population we are

dealing with must be maintained on their antipsychotic in order to
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prevent the relapse of their psychotic symptomotology , this would make
bupropion an ideal pharmacotherapeutic agent for treating their
depressive symptomotology without increasing the chance that adverse
reactions will occur .
Bupropion hydrochloride is both chemically and pharmacologically a
novel antidepressant compound .

It is structurally unrelated to the

tricyclic antidepressants (TCA's) or monoamine oxidase inhibitors
(MAOI ' s) and is neither sedating, anticholinergic , nor cardiotoxic
(Dufresne et al . , 1984 ; Van Wyck Fleet et al . , 1983) .

More importantly ,

bupropion appears to be effective in treating Major Depression in many
patients who have in the past not responded to the TCA's and MAOI's
(Stern et al . , 1983).
While effective in treating major depression (Dufresne, et al 1984 ,
Preskorn and Othmer, 1984), it has not been established whether
bupropion can be useful in treating depression secondary to other
psychiatric syndromes .

Bupropion was chosen for this study because it

is chemically and pharmacologically distinct from the TCA's and the
MAOI ' s that have been used for this purpose in the past .

Unlike the

TCA ' s it does not block the reuptake of norepinephrine (NE) or of
5- hydroxytryptamine (5-HT) from synapses .

Also , it does not have any

effect on either type A or type B monoamine oxidase (Ferris et al ., 1981
and 1983) .

It has been demonstrated in a drug discrimination paradigm

in the rat that bupropion ' s internal cue is not blocked by neuroleptics
while that of the tricyclic antidepressants was so affected (Blitzer and
Becker, 1985 ).

This led us to hypothesize that bupropion might be

effective in treating depression in these patients when given
concomitantly with an antipsychotic since its mechanism of action might
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not be interfered with in the same manner as the TCA ' s .

Previous

studies in which the tricyclic antidepressant or monoamine oxidase
inhibitors did not decrease depressive symptoms when given concomitantly
with antipsychotic could be the result of the blockade of the more
typical antidepressants ' mechanism of action by the antipsychotic .

The

possibility that bupropion may work by a mechanism distinct fr om these
agents makes for the chance of it being effective where these
medications have previously failed .

Clinical studies in depressive

syndromes have demonstrated that bupropion is effective in patients
found refractory to TCA's (Stern, 1983) .

Furthermore , the fact that

bupropion is apparently a much safer medication than the MAOI ' s or TCA's
which are still often used in attempts to treat depressive symptoms
secondary to schizophrenia makes this study less of a risk to the
subjects than their usual treatment .

Bupropion, unlike TCA's , is not

likely to potentiate the anticholinergic or sedative effects of
antipsychotics as it does not possess these properties. (Van Wyck Fleet
et al . , 1983) . Unlike MAOI's , there is no concern about a possible
hypertensive crisis due to unmetabolized pressor substances such as
tyramine (Fowle et al . , 1983).
A secondary aspect of this study concerns whether the so called
"negative symptoms" of schizophrenia can be influenced by bupropion
treatment.

These negative symptoms of schizophrenia can be more readily

understood as deficit symptoms; that is , they describe the absence of
certain perceptual skills or emotive behavior that are found in
psychiatrically healthy individuals .

Examples of these symptoms include

anhedonia, apathy, emotional blunting, social isolation, poor hygiene ,
and poverty of speech.

These symptoms are often prominent in chronic

4.

schizophrenics and notoriously resistant to treatment (Andreasan, 1982) .
In a study of bupropion in major depressive syndrome Dr. Robert Becker
and myself found that patients became more active and interested in
their environment while receiving bupropion (Becker and Dufresne , 1982) .
Since withdrawal and emotional blunting are both prominent negative
symptoms of schizophrenia, interest as to whether bupropion could effect
these symptoms in schizophrenics was generated.
Other aspects of this study include assessment of adverse reactions
to the treatment and particularly the interactive eff ects of bupropion
and the antipsychotic thiothixene.

Thiothixene (Navane) was chosen as

the antipsychotic for this study due to previous evidence that it has
some mood elevat i ng properties when used in this patie nt population
( Becker, 1983) .

It appea rs to be a n adequate choice for treating this

population; therefore, by the desi gn of this study we a re not
withholding a pro ven treatme nt.

The major objective of t his s tudy was

to assess whether the bupropion-thiothixene combination is a better
treatment than thiothixene alone.

As bupropion will undoubtedly be used

in combination with antipsychotics in the treatment of these patients
upon its ma rketing in much the same manner as TCA's and MAOI's have been
used, it is as valuable to learn if bupropion is not useful for the
treatment of depression secondary to schizophrenia as it is to find that
it is useful in this application.
Methodology and Procedures
This was a 70 day study in which thirty-eight hospitalized,
depressed schizophrenic patients who received thiothixene in treatment
of their psychotic symptoms additionally received either bupropion
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(n=l9) or placebo (n=l9) in a double blind trial of efficacy and safety.
During an initial stabilization period of at least one week the dose of
thiothixene was adjusted to optimize antipsychotic response.

Patients

remained on the same dose of thiothixene for at least on week prior to
being started on bupropion or identical placebo; this dose of
thiothixene was fixed for the duration of the study.

After two weeks of

thiothixene treatment patients were required to meet a minimum score of
eighteen on the Hamilton Depression Scale.

Patients were then randomly

assigned to receive a flexible dosing regimen of either bupropion
150-750 mg/day or placebo for up to ten weeks in a double blind fashion.
The blind could not be broken according to Food and Drug Administration
regulations until study completion; the only exception was in the case
of a medical emergency.
Inclusion and Exclusion Criteria:
Patients were required to meet several strict inclusion and
exclusion criteria in order to be included in the study .

Each patient

at baseline was required to meet DSM-III Diagnostic Criteria for either
schizophrenia with superimposed atypical affective disorder or
schizoaffective illness (A.P.A., 1980).

The symptoms of the affective

componet of their illness had to be persistent for at least two weeks
prior to initial screening.

These depressive symptoms had to remain

prevalent during the the initial period in which they where stabilized
on thiothixene.

A minimum score of eighteen on the Hamilton Depression

Scale had to be assessed at initial screening, weekly through
thiothixene stabilization, and at baseline.

Treatment with TCA's or

MAOI's was not allowed for a minimum of two weeks prior to baseline.
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Patients were excluded from the study if they suffered from an organic
mental disorder, were incapable of conversation, had history or evidence
of a seizure disorder, had a history of alcoholism in past two years,
had a myocaridal infarction within the last two months, were pregnant or
lactating, or had a history of intolerance to phenothiazine or
thioxanthine antipsychotics.
Measures
Patients were assessed for therapeutic efficacy using the Brief
Psychiatric Rating Scale (BPRS), Hamilton Depression Scale, and Clinical
Global Impression Scale (Overall and Gorham, 1962; Hamilton, 1960, Guy ,
1976).

Extrapyramidal symptoms were assessed using the Dimascio

Extrapyramidal Symptom rating scale and symptoms indicative of tardive
dyskinesia were assessed using the Abnormal Involuntary Movement Scale
(Guy , 1976) .

The negative symptoms of schizophrenia were assessed using

the Brief Negative Symptom Scale (Dufresne et al ., in preparation) and
selected BPRS items.

A variation of the Treatment Emergent Symptom

Scale (Guy, 1976) was also included in the test battery to monitor for
any adverse reactions to study medications.

Each clinician assessed the

same patient from study e ntry through termination.
Clinical laboratory tests were obtained on study subjects prior to
baseline and at study termination.

These included hematology, clinical

chemistry, and urinalysis. Patients also received a thorough physical
exam, electrocardiogram, and electroencephalogram prior to and at the
termination of the study.

Vital signs were taken on each rating day to

assess for side effects such as orthostatic hypotension, hypertension,
or tachycardia.

These vital signs assessment included blood pressure
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supine and standing, heart rate supine and standing, weight, temperature, and respiratory rate.

Additional tests were ordered as necessary

for proper clinical care of the study patients.

Neurological side

effects were assessed using the Abnormal Involuntary Movement Scale and
the Dimascio Extrapyramidal Symptom rating scale at baseline, day 7, 14,
21, 28, 42,and 70 (Guy, 1976) .
Analysis
Safety assessments were made at day 0, 7, 14, 21, 28, 42, 56, and
70 of study treatment .

Safety assessments included an evaluation of

vital signs, electrocardiogram, electroencephalogram, SMA-12, CBC with
differential, and urinalysis as well as a complete physical exam .

These

tests were performed previous to and following the bupropion versus
placebo phase .

The assessments of therapeutic efficacy were analyzed

using analysis of variance with repeated measures over time (Winer,
1971).

Followup tests of simple effects or simple main effects were

performed in cases of significant overall ANOVA's with the Tukey A
procedure being employed to test for individual cell differences .
Statistical evaluation of side effect assessments was made using the
appropriate nonparametric techniques such as Wilcoxon sign test and
Chi-square test of independence (Marascuilo and McSweeney, 1977, Downie
and Starry, 1977).
This protocol has been approved by the Rhode Island Medical Center
Institutional Review Board and the University of Rhode Island
Institutional Review Board .

Written informed consent was obtained from

all subjects in accordance with federal regulations.

A pregancy

avoidance form was completed for every female who entered the study .
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RESULTS
Efficacy
The bupropion and thiothixene combination was no more efficacious
than the placebo and thiothixene combination.

On many measures the

control group was actually less symptomatic than the bupropion and
thiothixene treatment group.
Analysis of variance with repeated measures was performed on all
assessments for study periods ending at treatment day 28 and at day 70.
All but one patient in each treatment group finished 28 days of study
drug treatment; this was the minimal period of time a patient could
remain in treatment and still be considered a completed study patient.
Of the twenty-five patients who completed all ten weeks of the study,
nine were being treated with bupropion and thiothixene while sixteen
were those patients treated with placebo and thiothixene.
One of the difficulties in statistically analyzing results of
clinical trials is that a patient is as likely to drop out of a study
due to adverse reactions or lack of improvement while on a medication as
they are if they respond so dramatically to treatment that they are
discharged from the hospital.

Although each group had only one dropout

each at day 28, the patient dropout rate at day 70 was significantly
higher in the bupropion and thiothixene group than in the placebo and
thiothixene group (Chi-square= 5.729, df = 1, p

<

.02).

Nine of the

original nineteen patients completed ten weeks in the bupropion and
thiothixene group while sixteen of the nineteen thiothixene and placebo
treated patients completed ten weeks.

Of the bupropion group, the ten

subjects who did not complete 70 days of treatment were significantly
more symptomatic on the BPRS at termination (Student's t

=

2.29, p

<

9.

• 05, df

= 34)

than the nine subjects who did complete the full 70 days.

Patients who did not complete the full 70 days of bupropion therapy had
a mean score of 52.4 (S.D. = 17.15) on the BPRS at termination and those
who did complete treatraent had a mean score of 33.3 (S.D.

= 18.89).

This would indicate that the patients who dropped prematurely from the
bupropion group were more symptomatic than those who remained in
treatment for the full 70 days, and that the significantly higher
dropout rate was the result of deterioration rather than improvement.
Analysis of change from baseline to termination of the bupropion and
thiothixene group shows a mean improvement in those completing ten weeks
of 6.44 (S.D. = 15.39), while those failing to complete ten weeks
demonstrated a mean worsening of 3.30 points (S.D. = 16.19) on the BPRS.
Statistical comparison of change from baseline on BPRS of the bupropion
group patients fails to show a significant difference on Student's
t-test (t = 1.34, N.S.).

Thus, those patients who dropped out were more

severely ill than those who did ·not, but deterioration during the study
may not have been the main reason for this difference in psychiatric
state.
Dose-Response Relationships
Neither dose of thiothioxene (r
(r

2

=

2

= .03) or dose of bupropion

.02) was significantly correlated with syptomatic change as

measured by the Brief Psychiatric Rating Scale.

The marked difference

in dose of neuroleptic or antidepressant required to achieve therapeutic
response in individual patients is well known, and neither dose of
antipsychotic nor serum levels have ever shown a predictable dose
response curve (Tang , 1985).

Overall mean bupropion dose was 445.83
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mg. per day (S.D. = 413.16) while that of the thiothixene was 21.58 mg.
(S.D. = 16.23) per day.
Brief Psychiatric Rating Scale
In terms of psychotic features as measured on the Brief Psychiatric
Rating Scale, bupropion and thiothixene treated patients (N= 18) and
placebo and thiothixene treated patients (N=l8) both demonstrated
improvement over time

(F = 5.68, df = 4, 136, p < .0005) with the

control group again showing greater improvement (F= 2 .57, df = 4,136,
p < .05) over 28 days.

Analysis of variance for patients completing ten

weeks of treatment showed an overall improvement from baseline for both
groups (F = 9.34, df = 6, 138, p < . 0001) at each week post baseline
(Tukey A followup test, p<. 01 ).

However , the thiothixene and placebo

group (N=l8) became significantly less symptomatic than the thiothixene
and bupropion group (N=l8) on study days 14, 21 , and 28 for those
patients completing four weeks on study drug (See tables I and II).
Five principal factors have been identified by principal factor
analysis for the Brief Psychiatric Rating Scale (Guy, 1975).

The

content of these separate factors have been identified as representing
the symptom complexes of anergia, anxiety and depression, thought
disorder, hostility and suspiciousness, and activation.

There were no

significant changes between groups or over time on the hostility and
suspiciousness or activation factors.

Both groups showed significant (F

= 2.73, p <.OS, df = 4,136) improvement over time in terms of a
decrease in thought disorder.

While both gro ups demonstrated a

decreased score on the anxiety-depression factor over time (F

12.16,

p < .0001, df = 4,136), the placebo and thiothixene control group
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demonstrated significant improvement from baseline at all treatment
ratings (Tukey A test, p( . 01), whereas the bupropion group showed only
a transient improvement from baseline at week three (Tukey A test,
p

<

. 05) .

On the anergia factor, the thiothixene and placebo group

demonstrated a significant decrease from baseline at weeks one (p (.05)
through four (p

<

.01) as tested using the Tukey A procedure (Winer ,

1971). (See tables III through VI)
For the thought disorder factor on the Brief Psychiatric Rating
Scale, there was a significant trend for improvement over time (F
2 . 73, df

=

= 4,136, p( . 05) without a significant groups over time effect

being prese nt (See table VII).

Si gnificant improvement from baseline

occurred at weeks one and two (p ( .01) as well as week four (p < .05) .
Both groups revealed a lack of s ignificant changes on the hostilitysuspiciousness and the activation factors of the Brief Psychiatric
Rating Scale upon analysis of variance.
Clinical Global Impressions
Overall psychiatric state as measured by the Clinical Global
Impressions Scale improved significantly over time for patients
completing four weeks (F
completing all ten weeks (F

12.93, df

=

= 4,136 , p <. 0001) and for those

14 . 27, df

=

6,138, p <. 0001).

All mean

weekly ratings showed significant improvement from baseline (Tukey A
followup test, p (.001 ).

There were no between group differences as

measured with this assessment instrument (See tables VIII and IX) .
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Negative Symptoms and Depression
There were no differences in response to medication in terms of
negative symptoms (tables X and XI).

Both groups improved over time on

these symptoms at four weeks (F=4.88, p< .001, df
weeks (F=5.53, p< .0001, df = 6,138) .

4,136) and at ten

The greatest improvement occurred

at three weeks from baseline (F = 17.89, p( .001, df = 1,136), though
both groups maintained improvement from baseline (P<.05) for the course
of the study .
Depressive symptomotology as measured on the Hamilton Depression
Scale was similarly effected by both treatments over four weeks .
treatment and control groups got better over time (F
df

=

Both

15 . 87, p < . 0001,

= 4,136 ) as compared to baseline (table XII) though there was no

difference in efficacy between groups .

All post baseline ratings were

statistically significant from the baseline ratings though not diff e rent
from each other .

Patients remaining in the study for ten weeks (See

table XIII) also improved significantly over time (F

= 17 . 46, df = 6,

138, p < .0001), though there were no be tween group differences.
Analysis of variance for all ten weeks using the last score forward
method of handling of dropouts found that while both groups improved
over time (F = 13 . 29, df = 6, 216 , p < . 0001), the placebo and
thiothixene control group improved to a greater degree than the
bupropion and thiothixene treatment group (F= 4 . 51, df

= 6,216,

p < .0001).
Safety
Experience with bupropion when used concomitantly with
antipsychotic medication is rare; therefore this study is key to
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investigating any possible interactive effects of using bupropion in
combination with thiothixene .

Previous clinical trials have prohibited

the use of concomitant psychotropic medications with bupropion .
Analysis of clinical chemistry, hematology , and urinalysis data
demonstrated no statistically or clinically significa nt differences
between the control or treatment groups using repeated measures t-test
(See table XIV) .

Analysis of the data using the Wilcoxon sign test

found no differences between groups on physical exam, electroencephalogram, and electrocardiogram .

Two patients with abnormal electro-

cardiograms who still qualified to enter the s tudy both suffered from
left anterior hemi-block conducta nce disorders; these pa tie nts had no
difficulty tolerating treatment and showed no e vidence of any new
abnormalitie s.

Three patients with mild diabetes mellitus and one with

mild hypertension were managed wi t hout incident on t he study and
demonstrated no signs of worsening of their condition. One young male
patient developed a petechia during the course of treatment with
bupropion and thiothixene that subsided quickly after the withdrawal of
bupropion .

One middle aged female patient exhibited a mild transient

case of hypertension and tachycardia after one month on bupropion and
thiothixene that was likely linked to worsening in her psychiatric
condition .

There were no clinically significant alterations observed on

electroencephalogram at the termination of study medication for any
patient .
Data obtained on the Treatment Emergent Symptom Scale (Guy, 1976)
was analyzed using the chi-square test of independence to determine if a
difference in incidence of adverse effects was observed between groups .
The data was analyzed with consideration of the frequency of reported
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symptom per patient interview and examination for 28 days and for 70
days of study treatment (See table XV).
The bupropion and thiothixene treated patients reported more than
twice the incidence of dry mouth (Chi-square of 5.81 and 4.69, df = 1,
p < .05)

and constipation (Chi-square of 4.67 and 9.6, df = 1, p < .05)

than the placebo and thiothixene group at fo ur and ten weeks.

However a

greater percentage of placebo and thiothixene treated patients reported
an increase in appetite (Chi-squares of 3.10 and 6.95, p < .10 and
p < .01 respectively), menstrual disturbance (Chi-square of 4.40, df =l,
p < .05), and decreased sex drive (Chi-square of 2 . 85, p < .10) over
both four and ten weeks.
Examination for neurological adverse reactions using the Abnormal
Involuntary Movement Scale and Dimascio procedures (tables XVI, XVII,
XVIII , XIX) yielded expected results.

Little change occured in the

symptoms of tardive dyskinesia over four weeks in both the treatment
(n=l8) and the control (n=l8) groups and in those completing ten weeks
of study treatment on bupropion and thiothixene (N=9) and placebo and
thiothixene (N=l6).
Acute extrapyramidal system disorders as measured on the DiMascio
extrapyramidal symptom scale revealed that both groups demonstrated less
extrapyramidal system movements over time for four weeks (F = 6.33, df
4, 136, p< .0001) and for ten weeks (F = 3.71, df = 6, 138, p < .01).
This is to be expected after an extended period of neuroleptic
treatment.

Tolerance to pseudoparkinson like extrapyramidal system

disorders is known to occur with extended periods of neuroleptic
treatment.
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DISCUSSION
The lack of response to bupropion and thiothixene in comparison to
placebo and thiothixene is consistent with the results of similar
studies employing a tricyclic antidepressant and neuroleptic versus a
placebo and neuroleptic.

That is, the addition of an antidepressant to

the therapeutic regimen offered no clear advantage (Becker, 1970 and
1976; Siris, 1978) .

In a trial comparing chlorpromazine and imipramine

to the mood elevating antipsychotic thiothixene and placebo , Becker
demonstrated that the treatment regimens gave similar good response on
Hamilton Depression Scale, Brief Psychiatric Rating Scale, and the Katz
Adjustment scale while the chlorpromazine and imipramine group
experienced more sedative and cardiovascular side effects (Becker,
1976).

In a study of 64 depressed schizophrenics this same investigator

found a combination of amitriptyline and perphenazine to be no more
efficacious than perphenazine and placebo with the suggestion that the
amitriptyline may have interfered with the antipsychotic effect of the
perphanazine (Becker, 1970).

Brockington and collaborators demonsrated

no positive effects of adding amitriptyline to a regimen of
chlorprmazine in schizoaffective patients (Brockington et al.,1978),
while Prusoff found a group of depressed schizophrenics showed
improvement in depressive symptomotology with perphenazine and
amitriptyline when compared to amitriptyline alone (Prussoff et al.,
1978).

However, three-quarters of those receiving combined therapy in

Prussoff 's study experienced an increase in blood pressure and in
weight. In a review of the literature concerning the treatment of
depressed schizophrenics Siris found that there were conflicting
reports; some investigators reported an increase in positive
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schizophrenic symptoms and some alleviation of depression with addition
of tricyclic antidepressants or monoamine oxidase inhibitors while
others reported no significant differences in efficacy (Siris, 1978).
This study with the novel antidepressant bupropion shows a lack of
benefit of the combination of bupropion and thiothixene to the mood
elevating antipsychotic thiothixene alone.
In examining the result of a clinical pharmacology study, there a re
at least two key underlying issues t o consider.

First, in what way does

all the knowledge that has been obtained in terms of a drugs pharmacological effects express itself in the data?

What is consistent with

previous studies with the agent and what is not? Se condly, in what way
does what we know about the und e rl ying mecha nism and etiology of the
disease inte r a ct with what we know a bout the drugs pharma cologic
effects?

In understanding t hese r e lationships we can better understand

the implications of the findin gs and wh e re the y fit it i n t e rms of
clincal tr e atment for the di sease a nd f uture r e sea rch.
In terms of both the dise ase state of depression in schizophrenia
and that of the mechanism of action of bupropion - or for that matter of
any antidepressant - there are as many questions as answers .

Past

research into the clinical treatment of depression has been largely
empirical, with deductions as to how an antidepressant is effecting the
disease being inferred by what the treatment had in common with other
effective treatments . Curious but also not suprising is the manner in
which medicinal chemists have synthesized compounds structurally similar
to prior compounds, with pharmacologists selecting the compounds for
potential clincial trials based on their pharmacological similarity to
agents previously found effective . This circular phenomenon has resulted
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in many pharmacologically similar compounds that off er few new benefits
to the treatment of ps ychosi s or depres sjon .

The cycl e is broken when a

compound that does not possess a property previously thought integral to
it being efficacious is nevertheless found to be clinically effective.
For example, since effective antidepressants all had in common the
abilty to increase synaptjc NE or DA as did the MAOI's, the end effect
of increasing the synap tic catecholamine levels was considered crucial
to their mechanism of action for many years.

This theory is still

commonly cited as the mechanism of action in many pharmacology text
books despite the fact that this effect is immediate while clincial
response to antidepressants does not occur for at least two to three
weeks.
Fortunately, the use of behavioral models of depression in animals
has led to the development of novel antidepressant compounds that do not
inhibit the reuptake or breakdown of serotonin or of norepinephrine
(Shopsin et al., 1981).

One such compound is bupropion. The question

once more has become not if a compound works in depression but why does
it work?
A review of the literature examining the results of clincal trials
with bupropion in the treatment of major depressive syndrome reveal that
the compound is significantly more effective than placebo (Zung, 1983)
and is as effective as the positive control antidepressant amitriptyline
(Chouinard, 1983).

The medication has been found useful in all but a

few clinical trjals and has a side effect profile that rivals that of
placebo with the exception of its abiljty to cause seizures in
susceptible patients to the same degree as imjpramine (Dufresne et al.,
1984) .
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The existence of useful antidepressants such as bupropion that do
not significantly block catecholamine reuptake has led to the formation
of more inclusive theories as to the mechanism of action of
antidepressants.

The most recent theory that takes into account both

the temporal relationship of neurochemical event and remission of
depressive syptoms as well as the remarkable effectiveness of the so
called "second generation" antidepressants is that of post synaptic beta
receptor down regulation.

Clinically effective compounds such as

bupropion all seem to cause beta receptor subsensitivity at the same
time that remission from depressive symptoms is found to occur (Gandolf
et al, 1983; Sellinger-Barnette 1980)

though this effect is disputed

for bupropion (Ferris and Beaman, 1983).

The two to three week period

in which increased synaptic levels of norepinephrine a re found with the
TCA's or MAOI 's readily explains their abilty to cause post synaptic
beta receptor down regulation.

In what manner could a drug such as

bupropion, a drug pharmacologically disimilar to established
antidepressants , create its therapeutic effect?
Bupropion does not inhibit type A or Type B monoamine oxidase, nor
is it a potent blocker of NE or 5-HT reuptake (Ferris, R. M. et al.,
1983; Dufresne et al., 1984).

However, bupropion given before

intracisternal injection of 6-hydroxydopamine prevented destruction of
dopamine containing neurons via a dose related selective antagonism
(Cooper et al., 1980).

While studies conflict as to whether bupropion

effects serum prolactin levels (Stern et al., 1979;

Laakman, G., 1982),

the electroencephalogram arousal effect of bupropion in rats is
selectively blocked by the effective DA antagonist pimozide (Miller and
Wheatley, 1978).

Bupropion has a 100 fold less potent effect in
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blocking dopamine reuptake into nerve endings of rat striatum than
nomefensine.

The speculation as to bupropions mechanism of action has

therefore been focused on its small in vitro but apparently significant
in vivo effect on dopaminergic transmission.
Recent findings indicate that bupropions mechanism of action is
indeed dopaminergic in some manner.

One clinical trial demonstrated an

increase in serum homovanillic acid in depressed patients responding to
bupropion (Golden et al., 1984), while another investigator has shown
that bupropion may exert a DA facilitating effect by causing an increase
in receptor affinty for DA, perhaps in the manner that benzodiazepines
facilitate the binding of GABA to its receptor (Blitzer, 1985, personal
communication) .

A previous clinical trial reported an alteration in

perception with bupropion in some depressed patients in a manner similar
to that seen with dopaminergic agonistic drugs such as L- DOPA or
amantidine (Becker

& Dufresne, 1982). The fact that many of these

patients had been treated prior to the two week washout period at some
time with dopamine antagonistic neuroleptic leads to an interesting
speculation; could bupropion's small DA agonistic effect be amplified in
these patients due to supersensitive DA receptors? Only two of those ·
patients showing the altered perceptions showed any evidence of a
coexiting psychotic component to their illness. Furthermore, a
significant number of patients treated in this study showed signs of DA
stimulation such as hand tremor and agitation (Dufresne et al., 1985).
Nornefensine, an antidepressant that increases DA release as well as
inhibiting NE reuptake in synapses resembles bupropion in that it is
self-administered in rats and primates (Dufresne et al., 1984), has few
anticholinergic and cardiovascular side effects, and has an energizing
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stimulant effect in some patients (Shopsin et al., 1981).

When compare d

wi th ami tr yptyline in a lar ge double-blind tria l bupropion trea t ed
patients reported more agitation and excitement, nauseau and vomiting ,
and decreased appetite than the positive control (Chouinard, 1983).
these effects could be related to a dopamine agonistic mechanism.

All
An

increase in dopaminergic transmission could account for post synaptic
beta receptor down regulation.
Stepwise multiple regression was performed using the individual
items of the Negative Symptom Scale as predictors with change from
baseline on the Brief Psychiatric Rating Scale for both groups at day 28
(N

= 18 for both groups) being the dependent variable.

The single best

predictor of nonresponse to treatment was the presence of emotional
blunting.

The presence of emotional blunting has been linked to

enlargement of cerebral ventricles in schizophrenic patients (Andreasen,
1982) .

In this study, the presence of emotional blunting was an

indicator of poor response to thiothixene treatment.
was negatively correlated (r

Emotional blunting

= -.51) with improvement from baseline at

-

four weeks and was the best predictor of thiothixene treatment
nonresponse with a multiple R' of .2608 being observed (F=5.65, df
1,18 ,p

<

.05) .

No significant relationship between treatment

nonresponse and emotional blunting was found in the bupropion and
thiothixene treatment group patients.

This finding is one more atypical

difference in treatment response patterns between these groups that
leads to speculation that bupropion interfered with thiothixene's
mechanism of action in aleviating the anxiety and depression symptoms in
these patients.

Bupropions possible dopamine agonism worsened these

symptoms in our sample of depres s e d schizophrenics whereas the drug
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typically causes improvement in patients with major depressive syndrome.
The higher dropout rate of the placebo and thiothixene group at
days 42 and 70 could lead one to suspect that improvement may have
occured to a greater degree in this group partly due to their being able
to tolerate a longer period of treatment with thiothixene than the
bupropion and thiothixene group .

This finding also suggests a dopamine

agonistic effect of bupropion which interfered with the therapeutic
effect of dopaminergic receptor blockade of the thiothixene in a
subgroup of schizophrenics with a secondary depression .

Primarily

depressed patients should not, theoretically, be so effected.

In fact,

bupropion would reduce and not increase anxiety and depression in a
patient suffering from a primarily depressive disorder .
The results of the current study supports the possibility that
bupropion antagonized the therapeutic effect of thiothixene on some
parameters.

This would suggest that the effect of the mood elevating

antipychotics in treating depressed shizophrenia is related to the
unique effects that these drugs have in treating this syndrome .

That

is, bupropion causes an increase in dopaminergic transmission and
subsequent beta receptor down regulation that may cause improvement in
previously treatment resistant major depressive syndrome patients .
Increasing the release of DA into the synapse or the binding affinity of
DA to the receptor, as the case might be, would antagonize the
therapeutic effect that the thiothixene is having on the symptoms of a
syndrome that combines the symptomotology of major depressive syndrome
and the schizophrenias but is characteristically neither in its
neuropathology or in its response to pharmacologic intervention .
Treating the depressive component of the disease as a separate entity
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from the positive symptomotology of schizophrenia does not appear
rational, as antidepressants do not impove the depressive symptoms and
can exacerbate psychosis in many cases.

Rather, viewing the syndrome as

a disease which is distinct from major depressive syndrome and the
schizophrenias, but which exhibits symptomatic components of each,
offers a better structure in which to explore underlying pathology and
possible treatments for this syndrome .

Lack of any differences due to

bupropion on the Abnormal Involuntary Movement Scale may suggest that
bupropion ' s dopaminergic facilitating activity may be limited to
mesolimbic but not striatonigral dopaminergic systems .
Since the addition of antidepressants to antipsychotics in these
patients usually is ineffective, we may assume that this syndrome is
more similar to the schizophre nias in etiology and pathology than the
depressive spectrum disorders .

A possible explanation for the effect

that TCA's are found to ha ve in a f ew studies may be related to the
relief of antipsychotic induced akinetic symptoms due to the powerful
anticholinergic effects of amitriptyline and pharmacologically similar
antidepressants than relief of true depressive symptoms .

Previous

studies have shown the relief of akinetic syptoms in schizophrenics with
pseudo-parkinsonism using anticholinergic medication that in some cases
resembles the relief of many depressive symptoms (Van Putten and May ,
1978) .

The results of a factor analytic study also suggests that the

depressive symptoms of this syndrome is characteristically distinct from
that of major depressive syndrome or schizophrenia (Becker , 1985) .
Avenues for future research should focus on controlled double-blind
trials of single agents rather than combination therapies and further
work to characterize this syndrome as a separate psychiatric disease
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with a unique neuropathology requiring a unique pharmacotherapeutic
strategy.
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SUMMARY
Two groups of depressed schizophrenic patients were treated with
either bupropion and thiothixene or placebo and thiothixene and assessed
for efficacy and safety.

On the Brief Psychiatric Rating Scale total

scores , both groups improved over time at four and at ten weeks .
However, the placebo and thiothixene group did better than the bupropion
and thiothixene group over four weeks (F=2.57 , p
significantly so over ten weeks .

<

. 05) , though not

On the Brief Psychiatric Rating Scale

component scores for anxiety and depression , the placebo and thiothixene
group improved over time to a greater degree than bupropion and
thiothixene group .

For the anergia component score, the placebo and

thiothixene group improved significa ntly over time while the bupropion
a nd thiothixene group did not .

In re gard to t hought di s order, both

groups improved over time to a similar degree .

Neither group improved

over time on the acti vation or the hostility and suspiciousness
component scores.
On the Clinical Global Impression of severity of illness, both
groups improved over time at four and ten weeks , but neither group did
significantly better than the other.

In regard to depressive

symptomatology as measured on the Hamilton Depression Scale, both groups
improved significantly over time with no between group differences for
those patients completing both four and ten weeks .

On the Negative

Symptom Scale, both groups improved over time to a similar degree at
both four and ten weeks .
A significantly greater number of patients (N=9) dropped out after
four weeks of treatment in the bupropion and thiothixene group, while
only two patients in the bupropion and thiothixene dropped out between
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four and ten weeks of treatment with study medications.

This unequal

rate of premature study termination appeared to be the result of a
worsening in psychiatric condition.
The use of bupropion in addition to thiothixene in the treatment of
depressed schizophrenics appears to be unjustified and possibly
contraindicated.

The results and conclusions of this study is similar

to most well controlled clinical trials in which an antidepressant
medication is given in combination with an antipsychotic.
pharmacotherapeutic strategy is not recommended.

This
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Brief Psychiatric Rating Scale
Four Weeks
Bupropion &
Thiothixene
N=l8

Placebo &
Thiothixene
N=l8

Mean

S . D.

Mean

S . D.

Baseline

44 . 4

11.6

45 . 3

9.0

Day 7

38 . 1

16 . 3

36.4

11.8

Day 14

40 . 8

14 . 9

35 . 8

10 . 5

Day 21

41.0

19 . 7

35 . 3

11.4

Day 28

42 . 5

17 . 7

31. 9

10 . 9

Treatment
Period

Table I. Average scores for patients r ema i ning for four weeks on
drug for the Brief Psychiatric Rating Scale . Totals above thirty
on this scale represents a woderate l evel of psychotic symptoms ,
above forty-five represent s pronounced psychotic symptomotology,
and a total greater than sixty represents ve ry severe
psychopa thology . Placebo and thiothixene group improved
significantly over time while t he bupropion only group did not .
The placebo and thiothixene group demonstrated l es s
symptomotology (p < . 05) than the bupropion ond thiothixene gr oup
at day 14 , 21, and 28 .
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Brief Psychiatric Rating Scale
Ten Weeks
Bupropion &
Thiothixene
N= 9

Placebo &
Thiothixene
N = 16

Treatment
Period

MEAN

S.D.

MEAN

S.D.

BASELINE

39 .7

8.9

46.6

8.8

DAY 7

34.4

13.7

37 .4

11.9

DAY 14

34.7

12.4

36.0

11.1

DAY 21

29 .7

10.5

35 .4

12.1

DAY 28

32 .6

ll.6

32 .1

11.4

DAY 42

30.9

11.3

33 .4

11.8

DAY 70

33.2

16.4

29.5

8.8

TABLE II .

Brief Psychiatric Rating Sc a le tota l scores for those

patients completing ten weeks of study trea tme nt.
i mproved f r om base line (p

<

Bot h groups

. 001) while there was a trend for the

placebo and thiothixene group to have jmproved to a greater
degree

(p

<

. 10) over time •

Significantly more patients

dropped out of the bupropion and thiothixene group than the
placebo and thiothixene group .

34.

Anergia Factor Score
Bupropio n &
Thiothixene
N = 18

Placebo &
Thiothixene
N = 18

Treatment
Period

MEAN

S.D.

MEAN

S.D.

BASELINE

12.5

4.1

12.9

3.8

DAY 7

10.3

5.3

10.1

4.6

DAY 14

10.8

4.6

9.2

4.7

DAY 21

10.4

5.9

8.6

4.9

DP.Y 28

11.4

5.4

7.9

4.3

TABLE IIJ. Anergia factor score for the Brief Psychiatric scale .
The patients in the thiothixene and placebo ~roup improved
s ignificantly (p < .05) from baseline while the buproi:ion group
die not.

35 .

Anxie ty and Depression Factor

Treatment
Period

Bupropion &
Thiothixene
N = 18

Placebo &
Thiothixene
N = 18

MEAN

S.D.

MEAN

S.D.

BASELINE

12.4

3.2

13.6

2.9

DAY 7

10.6

5.0

9.9

3.9

DAY 14

11.3

5.5

9.7

3.4

DAY 21

9.8

5.1

9.1

3.5

DAY 28

10.8

5.0

8.0

3.7

TABLE IV.
Bupropion and thiothixene group improved from
baseline at week 3 only (p < .05) while placebo and thiothixene
group showed significant improvement on anxiety and depression
Brief Psychiatric Rating Scale factor score from baseline at week
one and thereafter (p < .01 ).

36.

BPRS Hostility and
Suspiciousness Factor Score
Bupropion &
Thiothixene
N = 18

Placebo &
Thiothixene
N = 18

Mean

S.D.

Mean

S.D.

BASELINE

5.2

2.5

5.2

2.3

DAY 7

4.9

2.8

5.1

2.6

DAY 14

5.4

3.2

4.7

2.0

DAY 21

6.3

4.8

4.8

2.9

DAY 28

6.8

4.3

4.7

2.4

Treatment
Period

TABLE V. Hostility and suspiciousness factor score for the
Brief Psychiatric Rating Scale for patients completing four
weeks. There were no significant differences between groups or
over time.

37 .

Activation Factor Score

Bupropion &
Thiothixene

Place bo &
Thiothixene

N = 18
S . D.
MEAN

N= 18
MEAN
S . D.

BASEL IKE

5.8

3. 3

5. 9

2 .7

DAY 7

5. 3

2. 8

5. 2

2 .4

DAY 14

5 .7

2.9

5.6

2.5

DAY 21

5.9

3.4

6. 1

3. 0

DAY 28

5. 4

3. 3

5. 3

2. 2

Treatmen t
Period

TABLE VI . Br i ef Psychiatrjc Rating Scale activation factor
score . There were no significant differences between groups or
over time .

38 .

Thought Disorder Factor Score

Bupropion &
Thiothixene
N = 18

Placebo &
Thiothixene
N = 18

Mean

S.D.

Mean

S.D.

BASELINE

8 .3

3 .8

8 .0

3.3

DAY 7

7.2

3.4

6. 4

2. 6

DAY 14

7.3

3 .3

6 .3

2. 5

DAY 21

7.5

3.7

7.2

2. 9

DAY 28

7. 9

3.8

6. 2

2. 3

Treatment
Period

TABLE VII . The thought disorder factor score of the Brief
Psychiatric Rating Sc~le for patients complet i ng four weeks.
There were no between group diffe r ences . Both groups demontrsted
a decrease i11 th ought disorder as compared from bas e line that was
statistically signifjcan t ( p< . 05) at dnys sev e n, fourteen, and
twenty-eight .

39.

Clinical Global Impressions

Bupropion &
Thiothixene
N = 18

Place bo &
Thiothixene
N
18

Mean

S.D.

Mean

S.D.

BASELINE

4.7

1.0

4.7

.67

DAY 7

4 .1

1.6

4 .1

.96

DAY 14

4.2

1.3

4.0

1.0

DAY 21

3.9

1.5

3.6

1.1

DAY 28

3 .9

1.5

3.6

1.1

Treatment
Period

TABLE VIII. Clinical Global Impressions Severity of illness
rating for patients completing four wee ks of treatment . A rating
of 1ine represe nts absence of ps yc hopathology. Ra tings of thre e
represents mild psychiatric illness, of four moderate illness ,
and of six severe psychiatric dysfunction. A rating of seven
is reservel for the most extre mely ill patient.
Both groups
show improvement (F=l2.93, df = 4,136 ,P < .0001) over time .
There were no between group differences.

40.

Clinical Global Impressions

Bupropion &
Thiothixene
N=9

Placebo &
Thiothixene
N = 16

Mean

S.D.

Mean

S.D.

BASELINE

4.5

1. 2

4.8

.66

DAY 7

3.8

1.6

4.3

. 86

DAY 14

3.9

1.4

4.0

1.1

DAY 21

3.4

1.3

3.6

1.2

DAY 28

3 .3

l. 3

3 .7

1.1

DAY 42

3. Lf

1. 3

3. 6

1.2

DAY 70

3.6

1.4

3. 2

1.0

Treatment
Period

TABLE IX. Clinical Global Impressions severity of illness
rating for patients completing ten weeks of treatment. Both
groups show improvement over time . There are no between group
differences .

41.

Negative Symptom Scale
Four Weeks

Treatment
Period

Bupropion

Placebo

& Thiothixene

& Thiothixene

N=l8

N=l8

Mean

S . D.

Mean

S . D.

Baseline

7. 0

3. 5

6 . 75

4 . 67

Day 7

3 . 93

3 . 82

5.62

4 . 86

Day 14

5.6

4 . 48

4 . 62

4 . 04

Day 21

3.66

4 . 15

4.06

4 . 42

Day 28

5 . 06

5. 09

4 . 38

4.66

Table X. Lack of significant changes on
Scale for patients completing fo ur weeks
Total scores of between five an d ten can
moderate levels of the negative syoptoms
above ten re prese nts pronounce d negati ve

the Negative Symptom
of study treatment .
be interpreted as ·
of sch i zoph renia, whi le
synptomotology .

42.

Negative Symptom Scale
Ten Weeks
Bupropion &
Thiothixene
N 9

Placebo &
Thiothixene
N = 16

MEAN

S .D.

MEAN

S.D.

BASELINE

5.6

3.0

7.4

4.7

DAY 7

3.6

3.3

6.1

5.0

DAY 11+

4.4

4.2

4.4

3.8

DAY 21

2.7

2.]

4.3

4.7

DAY 28

3.7

2 .8

4.6

4.8

DAY 42

3.2

2 .8

4.2

4.4

DAY 70

2.4

2 .2

3 .7

4 .0

Treatment
Period

TABLE XI .
( p

<

.OGl)

Both groups improved significantly over time
while there were no between group differences.

43.

Hamilton Depression Scale
Four Weeks

Treatment
Period

Bupropion &
Thiothixene
N=l8

Place bo &
Thiothixene
N=l8

Mean

Mean

S .D.

S.D.

EASELINE

28 .9

10 .3

32 .0

8 .16

DAY 7

20 .1

15.4

19.4

11.1

DAY 14

22 . 2

14.7

19.2

11.9

DAY 21

18 .9

15.4

17.9

12.6

DAY 28

22 .7

16 . 3

16 . 0

13 . 9

TABLE XII . Hamilton depression scale means for patients
finishing four wee ks . Total ratings a bove eigh t een are
considered to represent moderate depressive syoptomotology, while
total scores greater than thirty repre sent severe depressive
psychopathology. There were no significant differences between
bupropion and th i othixe ne versus the placebo and th i othixene
groups over time . Both groups ioproved significantly over time
(F=l5 . 87, p< . 0001) for all post baseline ratings .

44 .

Hamilton Depression Scale
Ten Weeks
Bupropion &
Thiothixene
Treatment
Perio d

N=9

Placebo &
Thiothixene
N=l6

MEAN

S . D.

MEAN

S. D.

BASELINE

23 .9

6 .6

31.8

8.6

DAY 7

15 .7

11. 7

19 . 4

11. 6

DAY 14

15 . 4

12 . 0

17 . 8

11. 9

DAY 21

12 . 0

12 . 6

16 . 2

12 . 0

DAY 28

14 . 7

12 . 4

14 . 8

13 . 8

DAY 42

12 . 0

11.1

14 . 4

12. . 5

DAY 70

13 . 1

16 . 5

10 . 7

11.3

TABLE XIII .

For study patients completing ten weeks, both groups

demonstrated improvement (P
Scale .

< . 01) on the Hamilton Depression

45.

TABLE XIV.
Clinical Laboratory Data
Bupropion &
Thiothixene
N=l8
Baseline
Termination
Mean S.D.
Mean
S.D.

Placebo
& Thiothixene
N=l8
Baseline
Termination
Mean S.D.
Mean
S.D.

HEMATOLOGY

----------------------------------------------------------------Hemaglobin

15.1

1.3

14.57

1.5

15.3

1.2

14.8

1.2

Hematocrit

44.8

3.9

44.5

3.4

45.l

3.4

43.9

3.7

RBC x 10l6

5.0

. 38

5.0

.49

5.0

.41

4.89

.44

Platlet
Estimate

All WNL

All WNL

Total
WBC x 10l3

8.3

7.6

2.8

All WNL
2.0

7.9

2.5

All WNL
7.4

2.6

Differential

----------------------------------------------------------------Neutrophils 65 . 9
(41-77% WNL)

7.4

63 . 0

9.6

64.3

10.5

61.56

7. 0

Lymphocytes 26.8
(22-44% WNL)

8.4

30.5

8.4

27.6

8.3

29.5

8.7

Monocytes
(3-6% WNL)

3.8

3.2

4.7

2.4

5.11

3.4

5.12

3.1

Eosinophils 2.8
(0-2.7% WNL)

2.3

1.5

1.5

2.11

2.1

3.00

2.7

.47.

TABLE XIV. (CONTINUED)
URINALYSIS
Bupropion &
Thiothixene
N=l8
Termination
Baseline
Mean S.D.
Mean S.D.
Specific Gravity 1.018 .007
(1.009-1.026 WNL)
Acetone

1.021

Placebo &
Thiothixene
N=l8
Baseline Termination
Mean S.D.
Mean S.D.

.009

1.016 .005 1.017 .005

0

0

0

0

Protein
0
(no. of positives)

0

0

1

Glucose

0

0

0

0

WBC

0

0

0

0

RBC

0

1

0

0

Table XIV. There were no significant differences between groups
for clinical laboratory tests of hematology, blood chemistry, or
urinalysis.

48.

TABLE XV.
TREATMENT EMERGENT SYMPTOM SCALE
BUPROPION & THIOTHIXENE
BASELINE

FOUR WEEKS

TEN WEEKS

15.79
5.26
10.53
5.26

8.74
1.94
16.50
5.83
3.88
15.53
15.59
5.83
9.71
0.00
3.88

ADVERSE REACTIONS
(Percent Reporting)
Hallucinations
Euphoria
Agitation
Irresponsible Behavior
Aggression
Insomnia
Tiredness
Drowsiness
Decreased Appetite
Increased Appetite
Headache

36.84
36.84
10.53
5.26
5.26
0.00

6.67
2.67
16.00
6.67
4.00
18.67
18.67
4.00
8.00
0.00
4.00

Myoclonus
Cramps
Rigidity
Tremor
Dystonia
Akathesia
Parasthesia
Tinnitus
Vertigo
Joint Pain
Muscle Pain

0.00
0.00
26.32
31.58
0.00
15.79
0.00
5. 26
5. 26
0.00
5.26

0.00
2.67
9.33
18.67
0.00
9.33
0.00 '
0.00
2.67
0.00
5.33

0.00
2.91
6.80
17.48
1. 94
7. 77
0.00
0.00
1. 94
0.00
3.88

Menstrual Disturbance
Blurred Vision
Dry Mouth
Increased Salivation
Constipation
Diarrhea
Urinary Retention
Nocturia
Sweating
Nauseau/Vomiting
Impotence

o.oo

o.oo

21.05
21.05
0.00
15.79
5.26
0.00
0.00
0.00
0.00
5.26

13.33
28.00
0.00
9.33
0.00
0.00
1.33
6.67
1.33

0.00
12.62
27.18
0.00
9.71
0.00
0.00
0.97
0.00
6.80
0.97

0.00
0.00

2.67
0.00
0.00
0.00

2.91
0.00
0.00
0.00

1.33
0.00
0.00
0.00

0.97
0.00

Fainting/Dizziness
Palpitations
Peripheral Edema
Cold Extremities
Skin Lesi on/Rash
Mem bran e Lesions
Alopecia
Hirsutism

o.oo

o.oo
0.00
0.00

o.oo

0.00
0.00

o.oo

o.oo
0.00

49.

TABLE XV. (Continued)
TREATMENT EMERGENT SYMPTOM SCALE
BUPROPION & PLACEBO
BASELINE

FOUR WEEKS

TEN WEEKS

15.79
5.26
10.53
5.26
0.00
36.84
36.84
10.53
10.53
10.53
10.53

10.81
1.35
9.46
5.41
1.35
24.32
16.22
1.35
4.05
4.05
6.76

9.76
1.63
6.50
3.25
.81
23.58
17.07
3.25
4.88
6.50
4.88

ADVERSE REACTIONS
(Percent Reporting)
Hallucinations
Euphoria
Agitation
Irresponsible Behavior
Aggression
Insomnia
Tiredness
Drowsiness
Decreased Appetite
Increased Appetite
Headache
Myoclonus
Cramps
Rigidity
Tremor
Dystonia
Akathesia
Parasthesia
Tinnitus
Vertigo
Joint Pain
Muscle Pain

0.00
5.26
21.05
5.26
5.26
21.05
0.00
0.00
0.00
5.25
5.26

0.00
1.35
12.16
21.62
2.70
12.16
1.35
0.00
0.00
12.16
16.22

0.00
0.81
12.20
20.33
1.63
9.76
0.81
0.00
0.81
10.57
13.01

Menstrual Disturbance
Blurred Vision
Dry Mouth
Increased Salivation
Constipation
Diarrhea
Urinary Retention
Nocturia
Sweating
Nauseau/Vomiting
Impotence

0.00
15.79
10.53
0.00
5.26
0.00
0.00
0.00
0.00
5.26
5.26

6.76
8.11
12.16
1.35
1.35
0.00
0.00
1.35
0.00
5.41
6.76

4.88
8.94
15.45
0.81
0.81
0.00
0.81
1.63
0.00
4.07
4.88

0.00
0.00
0.00
0.00

4.05
0.00
0.00
0.00

4.88
0.00
0.00
0.00

10.53
0.00
0.00
0.00

2.70
0.00
0.00
1.35

6.50
0.00
0.00
0.81

Fainting/Dizziness
Palpitations
Peripheral Edema
Cold Extremities
Skin Lesion/Rash
Membrane Lesions
Alopeci.a
Hirsutism

so.

Abnormal Involuntary Movement Scale
Bupropion &
Thiothixene

Bu pro pion

& Placebo
N=18

1~ =18

Treatment
Period

Mean

S. D.

Mean

S.D .

Baseline

3.0

5. 8

1.33

2.42

Day 7

2.1

4.1

1.61

2.35

Day 14

2. 5

5. 8

1. 94

3.28

Day 21

2. 8

5 .7

2 . 61

3 . 34

Day 28

2.9

5.6

1.61

2 . 54

Table XVI. No significant differences over four weeks on
symptoms of tardjve dyskinesia .

51.

Abnormal Involuntary Movement Scale
Ten Weeks
Bupropion &
Thiothixene
Treatment
Period

Placebo &
Thiothixene

N=9

N=l6

MEAN

S.D.

MEAN

S.D.

l~ASELINE

3.5

6.2

1.5

2.5

DAY 7

2.6

5.4

1.8

2.4

DAY 14

4.1

7.5

2.2

3.4

DAY 21

3.8

7.5

2.9

3.4

DAY 28

3 .3

7.0

1.8

2.6

DAY 42

3.5

7.0

2.8

3.7

DAY 70

3.3

7.5

2 .4

3 .4

TABLE XVII. No effects were demonstrated on tardive dyskinesia
symptoms for those patients
treatment.

com~leting

ten weeks of study

52.

DiMascio Extrapyramidal Symptom Scale
Bupropion &
Thiothixene

Placebo &
Thiothixene

Treatment
Period

Mean

S.D.

Mean

S .D.

Baseline

3 . 72

2.9

3.44

3.3

Day 7

2.39

2.8

2 . 22

1.6

Day 14

2.33

3 .1

1. 61

1.2

Day 21

2.22

3 .1

2 .22

2.2

Day 28

1.83

2.9

2.17

2.9

Table XVIII . Improvement on EPS for both groups over tr ea tment
period ( F=6 . 33, p<. 0001) . There was no sjgnificant difference
i n EPS symptoms be twee n groups for those patients completing four
weeks .

53.

Dimascio Extrapyrarnidal System
Disorder Scale
Ten Weeks
Treatment
Period

Bupropion &
Thiothixene

Placebo &
Thiothixene

N=9

N=l6

MEAN

S.D.

MEAN

S.D.

BASELIKE

2 .4

2. 1

3 .4

3 .3

DAY 7

1.3

0.9

2 .3

1. 7

DAY 14

1.4

1.2

1.6

1.3

DAY 21

1.3

1.8

2. 2

2.1

DAY 28

0.9

0 .7

2 .4

3 .0

DAY 42

0. 9

0 .7

2. 5

2. 5

DAY 70

0.9

1.6

1.4

1. 7

TABLE XlX .

Both groups demonstrated a decrease in extrapyramidal

system symptoms over time for those pa tients coopleting ten
weeks .

